Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
02/24/2023* 08:30 EST Earnings Call Q4 2022 -- -- --
02/24/2023* -- Results Q4 2022 -- -0.14 --
11/07/2022 08:30 EST Earnings Call Q3 2022 -- -- --
11/07/2022 -- Results Q3 2022 -0.12 -0.19 37.39%
08/04/2022 08:30 EST Earnings Call Q2 2022 -- -- --
08/04/2022 -- Results Q2 2022 -0.21 -0.22 4.55%
05/09/2022 08:30 EST Earnings Call Q1 2022 -- -- --
05/09/2022 -- Results Q1 2022 -0.27 -0.29 6.00%
*Estimated Date/Time

Earnings

Next Report Date 02/24/2023 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 11/07/2022
Beat/Miss Upgrade
Return Since 23.18%
Last FQE 09/30/2022
Next FQE 12/30/2022

Profile

Edit
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio.
URL https://www.amicusrx.com
Investor Relations URL https://ir.amicusrx.com
HQ State/Province Pennsylvania
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Feb. 24, 2023 (est.)
Last Earnings Release Nov. 07, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0.00%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
16.59%
-48.76%
189.5%
-33.43%
1.67%
137.1%
-49.98%
9.96%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-13.26%
42.42%
-45.76%
151.4%
-51.49%
-26.49%
37.02%
-75.08%
54.29%
--
-27.18%
-17.04%
-49.64%
3.57K%
-21.18%
-53.63%
103.5%
--
--
--
-75.17%
40.44%
364.4%
-76.63%
16.56%
472.1%
-10.52%
-32.67%
-24.58%
49.12%
-22.49%
9.34%
-29.48%
As of December 02, 2022.

Profile

Edit
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio.
URL https://www.amicusrx.com
Investor Relations URL https://ir.amicusrx.com
HQ State/Province Pennsylvania
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Feb. 24, 2023 (est.)
Last Earnings Release Nov. 07, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
PBE 6.502M USD 2.53%
BBP 369840.0 USD 2.19%
SBIO 2.044M USD 1.91%
APSRX 1.366M USD 1.67%
XBI 88.67M USD 1.15%
IHE 4.657M USD 1.12%
BTEC 477042.0 USD 0.88%
PHPSX 33207.00 USD 0.76%
F00000M14B 973008.0 USD 0.62%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Nasdaq Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter FOLD Tweets